newsfilter
← Latest News
GlobeNewswire·

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered